Macrogen
Macrogen is a South Korean biotechnology company providing genomic sequencing, analysis, and related research services.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Macrogen, Inc. is a South Korean biotechnology company headquartered in Seoul and focused on genomic research services, DNA sequencing, genome analysis, and related solutions for biotechnology, academic, clinical, and pharmaceutical users. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It initially developed as a venture-capital-backed research-services business and pursued a low-cost position in genomic testing and sequencing. Macrogen went public on the KOSDAQ market in 2000, becoming the first Korean biotechnology company to raise capital through an initial public offering according to the company’s historical account in the cited reference material. The company’s core business model has centered on serving other organizations engaged in biotechnology research and development rather than relying primarily on consumer products. DNA sequencing was reported to account for approximately half of Macrogen’s revenue in 2005, illustrating the importance of sequencing services to its early commercial model. After its IPO, Macrogen placed greater emphasis on developing and adopting sequencing technologies as a way to differentiate itself from lower-cost service providers. Its capabilities have included large-scale DNA sequencing, genome analysis, and services supporting research laboratories and clinical genomics workflows. Macrogen expanded internationally through subsidiaries, branches, and service relationships. It established Macrogen Corp. in the United States in 2004; that entity became Psomagen Inc. in 2019. The company opened its first European branch office in Amsterdam in 2008 and converted the European operation into Macrogen Europe BV in 2017. This international structure supported Macrogen’s work with overseas academic institutions, biotechnology companies, and clinical or research laboratories. A notable technology investment occurred in January 2014, when Macrogen became one of the first customers of Illumina’s HiSeq X Ten sequencing system. The platform was presented at the time as a major step toward reducing the cost of whole-genome sequencing and reaching the so-called $1,000 genome threshold. Macrogen also licensed GenoLogics’ Clarity LIMS in late 2014 for use in clinical and research genomics laboratory workflows, initially linking the system with its United States-based Macrogen Clinical Laboratory. Macrogen announced plans in 2010 to map what it described as the Korean genome. The initiative reflected an argument that earlier genome-mapping efforts supported by the United States had been disproportionately representative of populations of European or Caucasian ancestry, rather than fully representative of humanity. By 2015, external coverage characterized Macrogen as a global leader in personalized genomic medicine. The company has also competed for institutional sequencing and genome-analysis contracts, including successful bids in 2014 and 2015 to provide genome analysis services to University College London. Corporate leadership has changed over time. Founder Jeong-sun Seo remained chairman as of 2015. HyungTae Kim was identified as chief executive officer in 2014, while Hyon-yong Chong held the CEO role by early 2015. The cited material does not establish the company’s current executive roster, ownership structure beyond noting a high proportion of individual shareholders in historical KOSDAQ statistics, or a current corporate website and ticker symbol. Macrogen remains an active public biotechnology brand whose identity is principally associated with research-grade sequencing, genomic analysis, and the international delivery of genomic laboratory services.
History
Macrogen was established in 1997 by Jeong-sun Seo, a Seoul National University professor, as South Korea’s genomics and biotechnology sector was beginning to develop. The company initially operated as a venture-capital-backed research-services enterprise. Its early commercial proposition emphasized cost-efficient support for biotechnology research, with DNA sequencing forming a central part of its service portfolio. Historical reporting cited in the reference material indicates that sequencing accounted for about 50 percent of revenue in 2005. Macrogen’s strategic direction changed after its 2000 initial public offering and KOSDAQ listing. The listing made it, according to the cited account, the first Korean biotechnology company to raise funds through an IPO. Rather than competing solely on price, the company increasingly invested in sequencing technology and sought to distinguish itself through scale, technical capability, and access to newer platforms. This shift helped establish the company as a service provider for organizations that needed genomic data generation and analysis without building all of the required infrastructure internally. In 2004, Macrogen created Macrogen Corp. in the United States, extending its services into one of the world’s largest biotechnology and academic research markets. The United States operation later became Psomagen Inc. in 2019. Macrogen entered Europe through an Amsterdam branch office established in 2008; the European business was subsequently organized as Macrogen Europe BV in 2017. These overseas operations formed part of a broader international network of offices and subsidiaries serving research institutions and biotechnology customers. The company also pursued projects connected with population genomics. In 2010, Macrogen announced plans to map the Korean genome. The initiative was presented against the concern that major genome-mapping efforts supported by the United States had been based disproportionately on people of Caucasian or European ancestry, despite being described as representative of the human genome. Macrogen’s Korean-genome effort therefore reflected both a scientific objective and an attempt to broaden the population representation of genomic reference data. Technology acquisition was a recurring feature of Macrogen’s development. In January 2014, the company was among the earliest purchasers of Illumina’s HiSeq X Ten system. At the time, the platform was promoted as an important advance toward making whole-genome sequencing available at a cost near $1,000. Macrogen also licensed the Clarity LIMS platform from GenoLogics in late 2014. The laboratory-information system was intended for clinical and research genomics workflows and was initially to be integrated with the company’s United States-based Macrogen Clinical Laboratory. Macrogen used competitive contracts and institutional collaborations to expand its genomics business. In 2014 and 2015, it won competitive bidding rounds to supply genome-analysis services to University College London. External coverage in 2015 described Macrogen as a global leader in personalized genomic medicine, reflecting the company’s positioning at the intersection of high-throughput sequencing, computational analysis, and individualized medical research. Leadership changed during this period. HyungTae Kim was identified as CEO in 2014, while Hyon-yong Chong was serving as CEO by early 2015. Founder Jeong-sun Seo continued as chairman as of 2015. The cited historical material also noted that more than 90 percent of Macrogen’s outstanding shares were held by individual investors according to KOSDAQ statistics at that time. The available reference material does not provide a complete current management roster, detailed financial history, or a full account of later product developments. Macrogen’s established identity, however, remains that of a publicly listed South Korean biotechnology company offering sequencing, genome analysis, and related research and clinical genomics services through domestic and international operations.
- 2019
United States operation becomes Psomagen
[1]Macrogen Corp. in the United States changed its name to Psomagen Inc.
- 2017
European operation becomes a subsidiary
[1]Macrogen’s Amsterdam-based European operation became Macrogen Europe BV.
- 2014
HiSeq X Ten system adopted
[1]Macrogen became an early customer of Illumina’s HiSeq X Ten sequencing platform.
- 2010
Korean genome-mapping initiative announced
[1]Macrogen announced plans to map the Korean genome and broaden the population representation of genomic reference data.
- 2008
European expansion begins in Amsterdam
[1]The company opened its first European branch office in Amsterdam.
- 2004
United States subsidiary established
[1]Macrogen established Macrogen Corp. in the United States to support its international genomics-services business.
- 2000
Initial public offering and KOSDAQ listing
[1]Macrogen completed an IPO and listed on KOSDAQ, reportedly becoming the first Korean biotechnology firm to raise funds through an IPO.
- 1997
Macrogen is founded
[1]Jeong-sun Seo founded Macrogen in South Korea as a biotechnology and genomic research-services company.
Products and positioning
A technology-oriented, internationally operating genomics services provider serving biotechnology, academic, pharmaceutical, and clinical research organizations.
Genomic research service
DNA sequencing services
Macrogen’s foundational commercial offering is sequencing performed for external biotechnology companies, academic institutions, and research laboratories. The service model supports customers that need DNA data generation without owning comparable sequencing infrastructure. Sequencing was reported to represent approximately half of company revenue in 2005, making it a central part of Macrogen’s early business.
Genomics
Whole-genome sequencing and analysis
Macrogen provides large-scale genome sequencing and analytical capabilities for research and institutional projects. Its adoption of Illumina’s HiSeq X Ten platform in 2014 supported the company’s effort to compete through technology and scale as whole-genome sequencing costs declined.
Clinical genomics · 2014
Clinical and research genomics laboratory services
The company’s clinical and research genomics activities connect sequencing and interpretation with laboratory workflows. Macrogen planned to integrate the Clarity LIMS system with offerings from its United States-based Macrogen Clinical Laboratory, supporting sample and data management in clinical or research environments.
Precision medicine
Personalized genomic medicine
Macrogen has been positioned as a provider of genomic information relevant to personalized medicine. The offering is based on sequencing, genome analysis, and interpretation for research and clinical applications rather than a single consumer product. External coverage in 2015 described the company as a global leader in personalized genomic medicine.
Brand decisions
2014
Adoption of Illumina HiSeq X TenStrategyBackground
After its IPO, Macrogen sought to differentiate itself through sequencing technology rather than relying only on low-cost research services.
Action taken
Macrogen became one of the first customers to purchase Illumina’s HiSeq X Ten sequencing system.
Aftermath
The purchase strengthened Macrogen’s positioning in high-throughput sequencing during a period of rapid reductions in whole-genome sequencing costs.
2014
Clarity LIMS licensingOtherBackground
Clinical and research genomics laboratories require systems for managing samples, workflows, and associated data.
Action taken
Macrogen licensed Clarity LIMS from GenoLogics and planned an initial integration with its United States clinical laboratory.
Aftermath
The agreement supported the company’s effort to connect sequencing services with structured laboratory operations.
2010
Pursuit of a Korean genome referenceStrategyBackground
Macrogen argued that previous genome-mapping programs described as representative of the human genome had been disproportionately based on Caucasian or European populations.
Action taken
The company announced plans to map the Korean genome.
Aftermath
The initiative reinforced Macrogen’s role in population genomics and personalized genomic medicine, although the available material does not document the project’s final scientific outputs.
Recent events
- 2019
Macrogen’s United States operation becomes Psomagen[1]
Other
Macrogen Corp., established in the United States in 2004, became Psomagen Inc. in 2019.
- 2015
Macrogen again wins University College London genome-analysis work[1]
Other
Macrogen was reported to have won another competitive bidding round to provide genome-analysis services to University College London.
- 2014
Macrogen adopts Illumina HiSeq X Ten sequencing system[1]
Product launch
Macrogen became one of the first customers for Illumina’s HiSeq X Ten platform, a system associated at the time with substantially lower whole-genome sequencing costs.
- 2014
Macrogen licenses Clarity LIMS from GenoLogics[1]
Other
Macrogen licensed Clarity LIMS for clinical and research genomics laboratory workflows, with initial integration planned through its United States clinical laboratory.
- 2014
Macrogen wins University College London genome-analysis bids[1]
Other
Macrogen won a competitive bid to provide genome-analysis services to University College London.
- 2010
Macrogen announces plans for Korean genome mapping[1]
Other
Macrogen announced an initiative to map the Korean genome, arguing that earlier genome-mapping efforts did not adequately represent the genetic diversity of Asian populations.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/macrogen · Editorial policy · How profiles are compiled